Top Stories
ASCO Releases Rapid Guideline Recommendation Update for Patients With High-Risk, HER2-Negative, Germline BRCA–Mutated Breast Cancer

A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk, early-stage, HER2- breast cancer and germline BRCA mutations after completion of (neo)adjuvan

The ASCO Post
Copanlisib-Rituximab Combination May Improve Survival

The majority of patients (60%) had FL, 20.7% had MZL, 10.9% had small lymphocytic lymphoma, and 8.3% had lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.

Cancer Therapy Advisor

Head And Neck Cancer

Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis

Investigators review the literature on the tumor microenvironment as a key player in tumor growth and anti-cancer treatment responses in head and neck cancer.

Cancer Management and Research
Portrait of DNA Methylated Genes Predictive of Poor Prognosis in Head and Neck Cancer and the Implication for Targeted Therapy

Investigators conduct a systematic review to assess whether DNA hypermethylated genes are predictive of high risk of developing HNC and/or impact on survival and outcomes in non-HPV/non-tobacco/non

Scientific Reports
Fluorescein-Guided Panendoscopy for Head and Neck Cancer Using Handheld Probe-Based Confocal Laser Endomicroscopy

Confocal laser endomicroscopy has the potential for a rapid and histological assessment in the head and neck operating room.

Frontiers in Oncology
Saliva Test to Detect HPV-Associated Throat Cancer

A novel saliva test has been shown to detect HPV-associated oropharyngeal squamous cell carcinoma with high accuracy in a small study.

Masticatory Muscle Index for Indicating Skeletal Muscle Mass in Patients With Head and Neck Cancer

Investigators examine whether masticatory SMI measurements based on head and neck CT scans can be used to conduct sarcopenia assessments by evaluating whether M-SMI is correlated with L3-SMI.

Pembrolizumab Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

Dr Sacco and colleagues find the combination of pembrolizumab and cetuximab produces durable responses in patients with recurrent or metastatic HNSCC who had received no prior PD-1

The ASCO Post

FDA Approvals

FDA Approves New Pediatric Indication for Technetium Tc 99m Tilmanocept Injection

The Lymphoseek injection—a radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies—has been approved for pediatric use by the FDA.

The ASCO Post
FDA OKs First Targeted Therapy for Subset of Patients With NSCLC

The FDA approves amivantamab as the first targeted treatment for patients with NSCLC harboring epidermal growth factor receptor exon 20 insertion mutations.

FDA OKs Nivolumab After Surgery for Esophageal or GEJ Cancer

The FDA approves the adjuvant use of nivolumab in patients with resected esophageal or GEJ cancer who have received neoadjuvant CRT and have residual pathological disease following surgery.

FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic EGFR Exon 20 Insertion–Mutated NSCLC

The FDA approves amivantamab-vmjw for adult patients with locally advanced or metastatic NSCLC and EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease...

The ASCO Post
FDA Approves Avapritinib for Advanced Systemic Mastocytosis

The FDA approves the tyrosine kinase inhibitor avapritinib for adult patients with advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis, systemic mastocytosis...

The ASCO Post


Pharmacogenomics in Pediatric Oncology: Mitigating Adverse Drug Reactions While Preserving Efficacy

Major developments in drugs such as thiopurines and optimization in clinical trial protocols for treating cancer in children have led to a remarkable improvement in survival, from approximately...<

Annual Review of Pharmacology and Toxicology
The use of Hericium erinaceus and Trametes versicolor extracts in supportive treatment in oncology.

Substances available in nature with potential therapeutic effects are the subject of research that raises tremendous hopes for new challenges medicine.

Acta Pharmaceutica
Selecting Image-Guided Surgical Technologies in Oncology: A Surgeon's Perspective.

This study aimed to select the most promising IG technology per oncologic indication.

Journal of Surgical Research
Review of Oncology and Transplant Literature for the Management of Hepatic and Pancreatic Resections in Jehovah's Witnesses.

Jehovah's Witnesses undergoing liver or pancreas surgery represent a unique medical and ethical challenge.

Cancer medicine journal
Development and Optimization of Clinical Informatics Infrastructure to Support Bioinformatics at an Oncology Center.

Translational bioinformatics for therapeutic discovery requires the infrastructure of clinical informatics.

Methods of Molecular Biology

Lung Cancer

The Role of Radiomics in Lung Cancer: From Screening to Treatment and Follow-Up

This review identifies important recent publications to be synthesized into a comprehensive review of the current status of radiomics in lung cancer at each step of the patients’ care.

Frontiers in Oncology
Targeting Hyperactive TGFBR2 for Treating MYOCD Deficient Lung Cancer

Further analysis reveals that MYOCD potently inhibits stemness of lung cancer stem cells.

Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability

In order to comprehensively investigate the biochemical changes in platelets from cancers with high risk of thrombosis, investigators examine the platelet proteome of brain and lung cancer patients

Nivolumab/Ipilimumab Improves Overall Survival vs Chemotherapy in First-Line Treatment for Unresectable Malignant Pleural Mesothelioma

A prespecified interim analysis in the phase III CheckMate 743 trial has shown improved OS with first-line nivolumab/ipilimumab vs platinum-based CT in unresectable malignant pleural mesothelioma.<

The ASCO Post
​​Set of Genetic Markers in Lung Cancer Identified

Investigators at Wake Forest School of Medicine have identified a set of new genetic markers that could potentially lead to new personalized treatments for lung cancer.

Oncology Times - Latest Articles
Pathogenic Role of Epstein–Barr Virus in Lung Cancers

In this article, investigators review the current understanding of the EBV-LC association and the etiological role of EBV in lung carcinogenesis.


Immuno Oncology

Standardization & Harmonization of Immuno-Oncology Toxicities

A report from the Association of Community Cancer Centers shows that IO treatment is increasingly being given to patients in community settings, not just in academic cancer centers.

Oncology Times - Latest Articles
Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application

STING agonists, as novel agonists, are used in preclinical research and in the treatment of various tumors via clinical trials and have displayed attractive application prospects.

OncoTargets and Therapy
mRNA in Cancer Immunotherapy: Beyond a Source of Antigen

Many novel immunotherapeutic strategies focus on the use of mRNA beyond its use as the source of tumor antigens. 

Molecular Cancer
Cardiovascular Risks Associated With Checkpoint Inhibitors and CAR T-Cell Therapy

Leveraging the immune system to treat cancer, however, also increases the potential for serious off-target effects.

The ASCO Post
The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy

This review focuses on m6A-associated regulation, mechanisms, and functions in acquired chemoresistance, radioresistance, and resistance to immunotherapy in cancer.

Frontiers in Oncology
Clinical Sequencing to Assess Tumor Mutational Burden as a Useful Biomarker to Immunotherapy in Various Solid Tumors

Tumor mutational burden has been considered as a useful marker to indicate patients who benefit from ICIs.

Therapeutic Advances in Medical Oncology

Gastrointestinal Cancer

Addition of First-Line Nivolumab to Chemotherapy in Advanced Gastric Cancers

The phase III CheckMate 649 trial shows that the addition of first-line nivolumab to CT results in improved overall and PFS among patients with advanced HER2- gastric, GEJ, and...

The ASCO Post
Adjuvant Imatinib Therapy Offers Survival Benefit in Patients With Resected GIST, but Team Effort May Be Needed to Reduce Early Discontinuation Rates

Clinical trial data show that adjuvant imatinib improves RFS as well as OS, when administered for at least 3 years, among patients who undergo a macroscopically complete resection of a primary GIST

The ASCO Post
PET Response–Adapted Chemoradiotherapy for Esophageal and Esophagogastric Junction Adenocarcinoma

Mature results of the phase II CALGB 80803/Alliance trial indicate that treatment guided by early PET assessment of response to induction neoadjuvant CT improves pathologic complete response rates

The ASCO Post
A Nomogram for Predicting Risk of Thromboembolism in Gastric Cancer Patients Receiving Chemotherapy

The aims of this study are to develop and validate a novel nomogram to predict thromboembolism in gastric cancer patients receiving chemotherapy and to test its predictive ability.

Frontiers in Oncology
Novel Prognostic Biomarkers in Gastric Cancer: CGB5, MKNK2, and PAPPA2

The present study uses bioinformatics to identify prognostic markers for gastric cancer that would guide the clinical diagnosis and treatment of this disease.

Frontiers in Oncology
Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Advanced Esophageal Cancer

The trial evaluated first-line treatment with nivolumab plus chemotherapy or nivolumab plus ipilimumab in patients with advanced disease.

The ASCO Post

Skin Cancer

High-Dose Interferon or Ipilimumab vs Pembrolizumab for High-Risk Resected Melanoma

Patients with high-risk melanoma who had a course of pembrolizumab had longer recurrence-free survival than patients who received either ipilimumab or high-dose interferon after surgery.

The ASCO Post
Health-Related Quality of Life With Adjuvant Pembrolizumab vs Placebo in Resected Stage III Melanoma

An analysis of this trial shows no clinically significant decline in health-related quality of life with adjuvant pembrolizumab vs placebo in resected high-risk stage III melanoma. 

The ASCO Post
Patterns in the Development of Melanoma Across Body Sites

An international research team examined patterns in the development of melanoma in patients in Australia and the United Kingdom and shed light on possible relationships by anatomical site.

Cancer Therapy Advisor
Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma

Current guidelines for postoperative management of patients with stage I-IIA cutaneous melanoma do not recommend routine cross-sectional imaging...

JCO Precision Oncology
PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma

Investigators retrospectively analyze plasma DNA of patients with advanced melanoma treated with PD-1 antibodies, nivolumab or pembrolizumab, for five PD-1 genotype single nucleotide polymorphisms.

Frontiers in Immunology
Ultrasound-Mediated Microbubble Destruction Inhibits Skin Melanoma Growth by Affecting YAP1 Translation Using Ribosome Imprinting Sequencing

In this study, tumor tissue samples are collected from 64 CMM patients.

Frontiers in Oncology

Gynecologic Cancer

Overexpression of LINC00673 Promotes the Proliferation of Cervical Cancer Cells

This study examines the expression of LINC00673 in cervical cancer and cervical intraepithelial neoplasia and explores the role of LINC00673 in the development of cervical cancer.

Frontiers in Oncology
ALOX5AP Predicts Poor Prognosis by Enhancing M2 Macrophages Polarization and Immunosuppression in Serous Ovarian Cancer Microenvironment

Given the importance of the immune-related tumor microenvironment in ovarian cancer, investigating tumor-immune interactions and identifying novel prognostic and therapeutic targets in SOC is a...<

Frontiers in Oncology
Metabolic Inhibitor Shows Antitumor Effects in Ovarian Patients

The glutaminase inhibitor IACS-6274 appears to be well-tolerated with successful target inhibition and early signs of anti-tumor activity in a biomarker-driven Phase I trial.

Oncology Times - Latest Articles
Lack of Standardized Screening Linked to Increased Incidence of Many HPV-Related Cancers

While the annual incidence of cervical cancer in the US is on the decline, the incidence of other cancers related to HPV continues to increase, according to a study being presented at the 2021 ASCO

Cancer Therapy Advisor
Survival Outcomes in Patients With 2018 FIGO Stage IA2–IIA2 Cervical Cancer Treated With Laparoscopic Versus Open Radical Hysterectomy

The objective of the study is to compare the survival and recurrence outcomes between open and laparoscopic RH for stage IA2-IIA2 cervical cancer based on...

Frontiers in Oncology
Predicting Response to Endocrine Therapy in ER-Positive Breast Cancer

Hormone therapy is designed to stop the effects of estrogen on the tumor and can be very effective for ER+ breast cancer. 

Oncology Times - Latest Articles


The Regulation of miR-320a/XBP1 Axis Through LINC00963 for Endoplasmic Reticulum Stress and Autophagy in Diffuse Large B-Cell Lymphoma

This study incorporates fundamental research referring to considerable amounts of gene-sequencing data and bioinformatics tools to analyze the pathological mechanisms of DLBCL.

Cancer Cell International
Bone-Protecting Agents Reduce Fractures Associated With Treatment in Metastatic Castration-Resistant Prostate Cancer

Bone-protecting agents reduce the risk of bone fractures in patients with mCRPC who receive enzalutamide, with or without radium-223, according to results from a phase 3 trial.

Cancer Therapy Advisor
Pasireotide Plus Everolimus Improves PFS in Advanced Neuroendocrine Tumors of the Lung or Thymus

Phase 2 data show a progression-free survival benefit with the combination of pasireotide and everolimus in patients with advanced neuroendocrine tumors of the lung or thymus.

Cancer Therapy Advisor
Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study investigators aim to evaluate the antitumour activity and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL.

The Lancet Oncology
Addition of First-Line Nivolumab to Chemotherapy in Advanced Gastric Cancers

The phase III CheckMate 649 trial shows that the addition of first-line nivolumab to CT results in improved overall and PFS among patients with advanced HER2- gastric, GEJ, and...

The ASCO Post
Deep Learning for Diagnosis and Survival Prediction in Soft Tissue Sarcoma

Clinical management of soft tissue sarcoma is particularly challenging. Here, investigators use digital pathology and deep learning for diagnosis and prognosis prediction of STS.

Annals of Oncology

source list reference



Novel Prognostic Biomarkers in Gastric Cancer: CGB5, MKNK2, and PAPPA2
Frontiers in Oncology
All-Cause Mortality Risk With Adjuvant vs Early Salvage Radiotherapy After Radical Prostatectomy
The ASCO Post
Prolonged COVID-19 Common Among Patients With Lymphoma